Moreover, treatment of OXPHOS-competent hereditary leiomyomatosis RCC with the complex I inhibitor IACS-010759 plus simultaneous inhibition of the glycolytic enzyme phosphogluconate dehydrogenase (PGD) led to synthetic lethality [231]. This evidence concerns the gene PGD and hereditary leiomyomatosis and renal cell cancer.